<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="206241">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00403715</url>
  </required_header>
  <id_info>
    <org_study_id>03-104</org_study_id>
    <nct_id>NCT00403715</nct_id>
  </id_info>
  <brief_title>Study of INS365 Ophthalmic Solution in Subjects With Dry Eye Disease</brief_title>
  <official_title>A Multi-Center, Double-Masked, Randomized, Placebo-Controlled, Dose-Ranging Study of Multiple Ocular Instillations of INS365 Ophthalmic Solution vs. Placebo in Subjects With Dry Eye Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <brief_summary>
    <textblock>
      The purpose of this trial is to compare the effectiveness and safety of INS365 Ophthalmic
      Solution with Placebo when applied topically in subjects with dry eye disease.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2001</start_date>
  <completion_date type="Actual">September 2002</completion_date>
  <primary_completion_date type="Actual">September 2002</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double-Blind</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change in dry eye testing measures and symptoms</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>change in dry eye testing measures and symptoms</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Dry Eye Disease</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>diquafosol tetrasodium (INS365) Ophthalmic Solution</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  best corrected visual acuity in both eyes of at least +0.7

          -  six-month documented history of dry eye disease

          -  at least mild severity in 2 of the 4 dry eye symptoms

          -  unanesthetized Schirmer score of less than or equal to 7mm

          -  corneal fluorescein staining of greater than or equal to 4 (out of 15)

        Exclusion Criteria:

          -  nasally stimulated Schirmer score of less than 3mm in subjects with an initial
             Schirmer score of 0mm

          -  ongoing contact lens wear

          -  current topical ophthalmic medication use
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amy Schaberg, BSN</last_name>
    <role>Study Director</role>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>November 2016</verification_date>
  <lastchanged_date>November 28, 2016</lastchanged_date>
  <firstreceived_date>November 22, 2006</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Dry Eye Syndromes</mesh_term>
    <mesh_term>Eye Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
